Alnylam Pharmaceuticals Soars on Clinical Data Update

Alnylam Pharmaceuticals

is trading higher on the session after reporting positive ALN-TTR02 clinical data. The company said it achieved positive clinical results from its Phase I trial with ALN-TTR02 for the treatment of TTR-mediated amyloidosis. Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Alnylam stated: "We are very excited with these new ALN-TTR02 results, where we have achieved very robust effects, including up to 94% reduction of serum TTR and a nearly 80% level of suppression sustained at one month with just a single dose. These results document an unprecedented level of clinical activity for RNAi therapeutics and strongly support advancement of this innovative program to meet the needs of ATTR patients" Alnylam Pharmaceuticals is currently trading at $15.55,a gain of $3.03 or 24.20%